Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Hirofumi Mikami(Chugai Pharma (United States)), Tomoyuki Igawa(Chugai Pharma (United States))
Cited by 22
Related Papers
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137
|Journal for ImmunoTherapy of Cancer|2024|13